A controlled comparison of cyclazocine and naloxone treatment of the paroled narcotic addict. 1975

T E Hanlon, and O L McCabe, and C Savage, and A A Kurland

A controlled, double-blind study of the comparative effectiveness of the narcotic antagonists, cyclazocine and naloxone, was undertaken in a metropolitan narcotic clinic offering an abstinence program involving urine monitoring and ancillary counseling services. Seventy male addict parolees were randomly assigned to 6-month treatment with either cyclazocine, 4 mg administered on a daily basis, or naloxone, 500-2,000 mg administered on a locally developed and researched 'contingent' basis, i.e., whenever there was indication of narcotic drug use (daily and contingent placebos were utilized to preserve the double-blind). Criteria of treatment effectiveness included narcotic drug usage, clinic attendance, length of participation in the program, disposition at 6 months, and incidence of side effects. The two subsamples of 35 individuals were similar with respect to relevant demographic characteristics. Examination of comparative effects revealed little to no significant differences between the two groups in terms of measures of program adherence, treatment outcome, and personal and social adjustment. Side effects were more prevalent among cyclazocine patients. Typically, these included moderately severe somatic effects and perceptual and cognitive disturbances.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008950 MMPI A personality inventory consisting of statements to be asserted or denied by the individual. The patterns of response are characteristic of certain personality attributes. Minnesota Multiphasic Personality Inventory
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D010465 Perception The process by which the nature and meaning of sensory stimuli are recognized and interpreted. Sensory Processing,Processing, Sensory
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D003496 Cyclazocine An analgesic with mixed narcotic agonist-antagonist properties.
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
January 1973, Proceedings. National Conference on Methadone Treatment,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
January 1974, The American journal of drug and alcohol abuse,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
January 1967, Current psychiatric therapies,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
January 1976, Journal of clinical pharmacology,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
August 1948, The Journal of the Medical Society of New Jersey,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
January 1965, Journal of the Mississippi State Medical Association,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
March 1966, Maryland state medical journal,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
January 1973, The International journal of social psychiatry,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
May 1968, The American journal of psychiatry,
T E Hanlon, and O L McCabe, and C Savage, and A A Kurland
October 1967, JAMA,
Copied contents to your clipboard!